Michele Buemi

Michele Buemi

Auto-generated profile, based on publicly available information

Michele Buemi

Chair of Nephrology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
Davide BolignanoDavide Bolignano
Davide Bolignano
ALAntonio Lacquaniti
Antonio Lacquaniti
Giuseppe CoppolinoGiuseppe Coppolino
Giuseppe Coppolino
VDValentina Donato
Valentina Donato
SCSusanna Campo
Susanna Campo
MBMichele Buemi
Michele Buemi
Background and objectives: Chronic kidney disease (CKD) has recently assumed epidemic proportion, becoming a troubling emerging cause of morbidity, especially if it progresses to terminal stage (ESRD). The authors aimed to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL), a novel specific biomarker of acute kidney injury, could predict the progression of CKD. Design, setting, participants, & measurements: Serum and urinary NGAL levels, together with a series of putative progression factors, were evaluated in a cohort of 96 patients (mean age: 57 ± 16 years) affected by nonterminal CKD (eGFR ≥15 ml/min/1.73 m2) of various etiology. Progression of CKD, assessed as doubling of baseline serum creatinine and/or onset of ESRD, was evaluated during follow-up. Results: At baseline, both serum and urinary NGAL were inversely, independently, and closely related to eGFR. After a median follow-up of 18.5 mo (range 1.01 to 20), 31 patients (32%) reached the composite endpoint. At baseline, these patients were significantly older and showed increased serum creatinine, calcium-phosphate product, C-reactive protein, fibrinogen, daily proteinuria, and NGAL levels, whereas eGFR values were significantly lower. Univariate followed by multivariate Cox proportional hazard regression analysis showed that urinary NGAL and sNGAL predicted CKD progression independently of other potential confounders, including eGFR and age. Conclusion: In patients with CKD, NGAL closely reflects the entity of renal impairment and represents a strong and independent risk marker for progression of CKD.

24 March 2009 in Kidney and Blood Pressure Research
Verified
Journal Article
Closed access
Davide BolignanoDavide Bolignano
Davide Bolignano
ALAntonio Lacquaniti
Antonio Lacquaniti
Giuseppe CoppolinoGiuseppe Coppolino
Giuseppe Coppolino
VDValentina Donato
Valentina Donato
MFMaria Rosaria Fazio
Maria Rosaria Fazio
MBMichele Buemi
Michele Buemi
Background/Aims: Renal tubulointerstitium plays an important role in the development and progression of diabetic nephropathy. Methods: With the present study, we aimed at evaluating the levels of neutrophil gelatinase-associated lipocalin (NGAL), a tubular stress protein, in serum (sNGAL) and urine (uNGAL) from a cohort of 56 patients with type 2 diabetes mellitus categorized into three groups (normoalbuminuria, microalbuminuria and diabetic nephropathy). Results: All groups showed increased NGAL values with respect to controls; interestingly, increased NGAL levels were already found in diabetic patients without early signs of glomerular damage (normoalbuminuric). Both sNGAL and uNGAL increased in parallel with the severity of renal disease, reaching higher levels in patients with manifest diabetic nephropathy. The assessment of Pearson coefficient evidenced significant relationships between sNGAL and, respectively, uNGAL, serum creatinine and GFR (inversely) and between uNGAL and, respectively, serum creatinine, proteinuria, albuminuria, serum albumin and GFR (both inversely). Conclusions: NGAL might play an important role in the pathophysiology of renal adaptation to diabetes, probably as a defensive mechanism aiming to mitigate tubular suffering. Furthermore, NGAL measurement might become a useful and noninvasive tool for the evaluation of renal involvement in diabetic patients as well as for the early diagnosis of incipient nephropathy.

1 March 2003 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
MBM. Buemi
M. Buemi
ECE. Cavallaro
E. Cavallaro
FFF. Floccari
F. Floccari
ASA. Sturiale
A. Sturiale
CAC. Aloisi
C. Aloisi
NFN. Frisina
N. Frisina
Erythropoietin (Epo) is a hydrophobic sialoglycoproteic hormone produced by the kidney and responsible for the proliferation, maturation, and differentiation of the precursors of the erythroid cell line. Human recombinant erythropoietin (rHuEpo) is used to treat different types of anemia, not only in uremic patients but also in newborns with anemia of prematurity, in patients with cancer-related anemia or myeloproliferative disease, thalassemias, bone marrow transplants, or those with chronic infectious diseases. The pleiotropic functions of Epo are well known. It has been shown that this hormone can modulate the inflammatory and immune response, has direct hemodynamic and vasoactive effects, could be considered a proangiogenic factor because of its interaction with vascular endothelial growth factor, and its ability to stimulate mitosis and motility of endothelial cells. The multifunctional role of Epo has further been confirmed by the discovery in the central nervous system of a specific Epo/Epo receptor (EpoR) system. Both Epo and EpoR are expressed by astrocytes and neurons and Epo is present in the cerebrospinal fluid (CSF). Therefore, novel functions of Epo, tissue-specific regulation, and the mechanisms of action have been investigated. In this review we have tried to summarize the current data on the role of Epo on brain function. We discuss the different sites of cerebral expression and mechanisms of regulation of Epo and its receptor and its role in the development and maturation of the brain. Second, we discuss the neurotrophic and neuroprotective function of Epo in different conditions of neuronal damage, such as hypoxia, cerebral ischemia, and subarachnoid hemorrhage, and the consequent possibility that rHuEpo therapy could soon be used in clinical practice to limit neuronal damage induced by these diseases.

14 August 2002 in Clinical Science
Verified
Journal Article
Closed access
PDF file
MBM. Buemi
M. Buemi
ECE. Cavallaro
E. Cavallaro
FFF. Floccari
F. Floccari
ASA. Sturiale
A. Sturiale
CAC. Aloisi
C. Aloisi
NFN. Frisina
N. Frisina
It is now widely known that erythropoietin (Epo) does not only affect the haematopoietic system, but it can be considered a multifunctional trophic factor with an effect on the general homoeostasis of the entire organism. The recent discovery of a specific Epo/Epo-receptor system in the central nervous system (CNS) and cerebrospinal fluid, independently of the haematopoietic system, has further paved the way for new studies aimed at investigating the different sites of cerebral expression of Epo and its receptor, the regulation of their expression and, finally, the effects that this hormone has on the development and maturation of the brain. A further aim has been to investigate how it influences CNS homoeostasis and neurotransmission in adult brain. Attention has also been focused on the neurotrophic and neuroprotective function of Epo in different conditions of neuronal damage, such as hypoxia, cerebral ischaemia and subarachnoid haemorrhage, and therefore on the possibility that human recombinant Epo therapy could soon be used in clinical practice, also to limit neuronal damage induced by these diseases.

26 February 2010 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Davide BolignanoDavide Bolignano
Davide Bolignano
Giuseppe CoppolinoGiuseppe Coppolino
Giuseppe Coppolino
ALAntonio Lacquaniti
Antonio Lacquaniti
MBM. Buemi
M. Buemi
Eur J Clin Invest 2010; 40 (3): 273–276 Neutrophil gelatinase‐associated lipocalin (NGAL), a small 25 kDa stress‐protein released from injured tubular cells after various damaging stimuli, is already known by nephrologists as one of the most promising biomarkers of incoming Acute Kidney Injury. Moreover, recent studies seem to suggest a potential involvement of this factor also in the genesis and progression of chronic kidney diseases. This brief review explores the new interesting involvement of NGAL in the experimental and clinical field of cardiovascular diseases, such as the pathogenesis and clinical manifestations of atherosclerosis, acute myocardial infarction and heart failure. It does not seem difficult that, in the next future, NGAL may become a new missing link between the kidney and the cardiovascular system.

6 April 2012 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
GNGiovanni Neri
Giovanni Neri
ALAntonio Lacquaniti
Antonio Lacquaniti
GRGiuseppe Rizzo
Giuseppe Rizzo
Nicola DonatoNicola Donato
Nicola Donato
MLMariangela Latino
Mariangela Latino
MBMichele Buemi
Michele Buemi
The diffusion of high-performance analytical technology has opened prospects for breath diagnosis as a non-invasive diagnostic tool. In this study, ion mobility spectrometry (IMS) and cavity ring-down spectroscopy (CRDS) techniques were used to analyse ammonia gas (NH3) in real-time in breath from patients undergoing haemodialysis (HD) treatment and any correlation with blood urea nitrogen (BUN) levels and Kt/V were investigated. We studied 20 patients on intermittent HD treatment. The first breath samples were taken before the start of dialysis and further breath samples were taken every hour during the treatment and after the end of the session. An evaluation was also made of 20 healthy volunteers, acting as controls [healthy subjects (HS)]. Breath ammonia concentrations were higher in CRDS-HD (914.5 ± 301.4 versus 280 ± 120 parts per billion (p.p.b.), P < 0.0001) and IMS-HD patients (964.4 ± 402.4 versus 280 ± 120 p.p.b., P < 0.0001) than in HS. We assessed real-time variations in the levels of NH3 and showed a continuous decrease in the levels of NH3. Expired NH3 correlated directly with BUN levels, both in the IMS-HD (P = 0.002; r = 0.84; P = 0.009; r = 0.76) and in the CRDS-HD group (P = 0.005; r = 0.80; P = 0.008; r = 0.77), respectively, both before and at the end of dialysis. A direct correlation with Kt/V was found in both groups studied (IMS-HD: P = 0.003; r = 0.82; CRDS-HD: P = 0.006; r = 0.79). Breath monitoring of NH3 with IMS and CRDS techniques could be useful to assess the real-time clinical status of patients during HD. By using pre-dialysis ammonia values, an approximate calculation of the Kt/Vurea ratio can be established.